Replies to post #26151 on Intellipharmaceutics International Inc. (IPCI)

[Tekterra]

This maybe the case since management is constantly evaluating the market and regulatory changes. They started off down the ANDA path, no reason why they can't continue doing so since they already have a good foundation built.

This year they are focusing on Rexista and potential partnership. I think FDA deliver what they are planning next year, I can see IPCI putting more ANDAs on their pipeline. The one filed recently for example, they might be anticipating an approval next year, or early 2019.